Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck astraZeneca (Lynparza & Koselugo Oncology Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q1 2023
250
Period ended Mar 31, 2023
Change on a year earlier
0.0%
250 in Q1 2022
History
5 quarters
Since Q1 2022
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2023 | Mar 31, 2023 | 250 | 0.0% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2022 | Sep 30, 2022 | 0 | – | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 0 | – | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 250 | – | Form 10-Q (filed 2022-05-05) ↗ |
Cite this data
StockData. (2026). Merck AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M), quarterly Q1 2022–Q1 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_astrazeneca_amort
See every metric in the Merck KPI table. Data updated Oct 26, 2026.